MX2018002067A - Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr. - Google Patents

Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.

Info

Publication number
MX2018002067A
MX2018002067A MX2018002067A MX2018002067A MX2018002067A MX 2018002067 A MX2018002067 A MX 2018002067A MX 2018002067 A MX2018002067 A MX 2018002067A MX 2018002067 A MX2018002067 A MX 2018002067A MX 2018002067 A MX2018002067 A MX 2018002067A
Authority
MX
Mexico
Prior art keywords
egfri
tetracycline
management
egfr inhibitor
tetracycline antibiotic
Prior art date
Application number
MX2018002067A
Other languages
English (en)
Inventor
Shirvan Mitchell
Berman Tal
Keynan Rita
Schuz David
Hazot Yohan
Eini Meir
Original Assignee
Foamix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foamix Pharmaceuticals Ltd filed Critical Foamix Pharmaceuticals Ltd
Publication of MX2018002067A publication Critical patent/MX2018002067A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan metodos de tratamiento y regímenes de dosificacion usando una composicion que comprende un antibiotico de tetraciclina en el tratamiento o alivio de un trastorno que incluye sarpullido asociado con EGFRI, síntomas relacionados con el sarpullido asociado con EGFRI, un trastorno relacionado con el sarpullido asociado con EGFRI que responde a antibiotico de tetraciclina, un trastorno de la piel causado por una bacteria, y una enfermedad de glandula sebacea que responde a antibiotico de tetraciclina, trastornos asociados con bacterias de sarpullido asociado con P. EGFRI y otras infecciones superficiales, incluyendo infecciones de la piel.
MX2018002067A 2015-08-20 2016-08-19 Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr. MX2018002067A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562207712P 2015-08-20 2015-08-20
US201562248008P 2015-10-29 2015-10-29
US201662345695P 2016-06-03 2016-06-03
PCT/IB2016/054989 WO2017029647A1 (en) 2015-08-20 2016-08-19 Tetracycline management of egfr inhibitor associated dermatoses

Publications (1)

Publication Number Publication Date
MX2018002067A true MX2018002067A (es) 2018-09-05

Family

ID=56877083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002067A MX2018002067A (es) 2015-08-20 2016-08-19 Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.

Country Status (4)

Country Link
US (1) US20180235984A1 (es)
CA (1) CA2995794A1 (es)
MX (1) MX2018002067A (es)
WO (1) WO2017029647A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
TWI717539B (zh) * 2017-07-25 2021-02-01 健喬信元醫藥生技股份有限公司 鼻用醫藥組合物及其製備方法及鼻用複方懸浮液
JP2021500369A (ja) * 2017-10-24 2021-01-07 グレンマーク・ファーマシューティカルズ・リミテッド アダパレン及びミノサイクリンの局所用医薬組成物
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
AU2019254237A1 (en) 2018-04-16 2020-12-03 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
EP0552612A3 (en) 1992-01-22 1993-10-20 Hoffmann La Roche Methods for determining and isolating compounds which bind directly to nucleosolic proteins

Also Published As

Publication number Publication date
US20180235984A1 (en) 2018-08-23
WO2017029647A1 (en) 2017-02-23
CA2995794A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2018006223A (es) Moduladores de ror-gamma.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2016009898A (es) Tratamientos para acne resistente.
MX2017007973A (es) Tratamiento de penfigo.
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MY188139A (en) Sodium channel modulators for the treatment of pain
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
BR112019008241A2 (pt) tratamento do prurigo nodular
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
IN2013MU03216A (es)
BR112018069174A2 (pt) tratamento de prurido urêmico
MY194135A (en) Treatment and diagnosis of inflammatory disorders
BR112016028402A2 (pt) toxina botulínica para uso no tratamento da paratonia